Status:
UNKNOWN
Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Weill Medical College of Cornell University
New York Presbyterian Hospital
Conditions:
Prostatic Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Developing a genetic study on localized or locally advanced prostate cancer. The aim of the study is to identify genomic alteration predictive of metastatic recurrence in the context of primary hetero...
Eligibility Criteria
Inclusion
- Patients managed by radical prostatectomy for prostate cancer between 2000 and 2016.
- Follow up \> 6 years
- Negative pre surgical extension assessment
- Prognostic Grade Groups (OGG) III-IV-V
- Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL
- Metastasis positive imaging
Exclusion
- Neoadjuvant therapy
- Follow up \< 6 years
- Prognostic Grade Groups (PGG) I-II
- Biochemical recurrence with metastasis negative imaging
Key Trial Info
Start Date :
May 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2020
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT03421015
Start Date
May 1 2017
End Date
July 1 2020
Last Update
November 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Claude Huriez, CHRU
Lille, France